Targeting bone metastases in prostate cancer: improving clinical outcome (Q38539641)

3 September 2017

1 reference

title

Targeting bone metastases in prostate cancer: improving clinical outcome (English)

1 reference

3 September 2017

1 reference

2

0 references

author name string

Jean-Jacques Body

series ordinal

1

1 reference

3 September 2017

Luís Costa

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

5 May 2015

1 reference

3 September 2017

Nature Reviews Urology

1 reference

3 September 2017

12

1 reference

3 September 2017

340-356

1 reference

3 September 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2015.90

3 September 2017

0 references

cites work

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Abiraterone and increased survival in metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Abiraterone in metastatic prostate cancer without previous chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Increased survival with enzalutamide in prostate cancer after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Alpha emitter radium-223 and survival in metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Study on the distribution features of bone metastases in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Reducing the burden of bone metastases: current concepts and treatment options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Pathogenesis of osteoblastic bone metastases from prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Osteoclast differentiation and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Metastasis to bone: causes, consequences and therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The distribution of secondary growths in cancer of the breast. 1889

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The critical role of the bone microenvironment in cancer metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Definition of molecular determinants of prostate cancer cell bone extravasation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Regulation of cancer cell migration and bone metastasis by RANKL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The role of Dickkopf-1 in bone development, homeostasis, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Molecular mechanisms and treatment of bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bone health in cancer patients: ESMO Clinical Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Current and emerging therapies for bone metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Recent advances in bone-targeted therapies of metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Novel therapies for metastatic castrate-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Pain and nociception: mechanisms of cancer-induced bone pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Molecular mechanisms of action of bisphosphonates: current status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A dose-finding study of zoledronate in hypercalcemic cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bisphosphonates for malignancy-related bone disease: current status, future developments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Dosimetry of 223Ra-chloride: dose to normal organs and tissues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

CYP17 inhibition as a hormonal strategy for prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Enzalutamide in metastatic prostate cancer before chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Consensus on the utility of bone markers in the malignant bone disease setting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Addressing genetic tumor heterogeneity through computationally predictive combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.90

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial

31 March 2020

1 reference

12 December 2020

Bone metastases: improving the therapeutic index

1 reference

12 December 2020

Clinical research update: zoledronate

1 reference

12 December 2020

Dosing regimens and main adverse events of bisphosphonates

1 reference

12 December 2020

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases

1 reference

12 December 2020

A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases

1 reference

12 December 2020

Sequencing of agents for castration-resistant prostate cancer

1 reference

12 December 2020

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

12 December 2020

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

1 reference

12 December 2020

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

1 reference

12 December 2020

Metastatic castration-resistant prostate cancer: critical review of enzalutamide.

1 reference

12 December 2020

Bisphosphonates and breast carcinoma: present and future

1 reference

12 December 2020

Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features.

1 reference

12 December 2020

Localization of androgen receptor expression in human bone marrow

1 reference

12 December 2020

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

1 reference

12 December 2020

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2015.90

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference